Mitchell L Martin

US Patent:

20040001832, Jan 1, 2004

Filed:

Nov 12, 2002

Appl. No.:

10/292576

Inventors:

Gayle Collin - Trenton ME, US
Jan Marshall - Mount Desert ME, US
Mitchell Martin - Verona NJ, US
Juergen Naggert - Bar Harbor ME, US
Patsy Nishina - Bar Harbor ME, US
W. So - Nutley NJ, US

International Classification:

A61K039/395
C12Q001/68
C07H021/04
C12N009/00
C12P021/02
C12N005/06
C07K016/40

US Classification:

424/146100, 435/006000, 435/069100, 435/320100, 435/183000, 435/325000, 530/388260, 536/023200

Abstract:

The present invention relates to a nucleic acid sequence linked to Alström syndrome, variants of that nucleic acid sequence, the protein produced by that nucleic acid sequence and screening methods for testing individuals to determine if they are carriers of Alström syndrome.

US Patent:

20040121395, Jun 24, 2004

Filed:

Dec 15, 2003

Appl. No.:

10/735991

Inventors:

Robert Goodnow - Basking Ridge NJ, US
David Mark - West Windsor NJ, US
Mitchell Martin - Verona NJ, US
James Rosinski - Nutley NJ, US

International Classification:

C12Q001/68
G01N033/53
G01N033/567

US Classification:

435/006000, 435/007200

Abstract:

Sequence #115, a G protein-coupled receptor, has been identified as a target for identifying weight modulating compounds. Compounds that modulate sequence #115 are useful for the treatment of obesity and cachexia. Cell-based and cell-free assays are described to identify compounds which bind to and/or activate or inhibit the activity of sequence #115.

US Patent:

20050074805, Apr 7, 2005

Filed:

Sep 28, 2004

Appl. No.:

10/952459

Inventors:

Jarema Kochan - Towaco NJ, US
Mitchell Martin - Verona NJ, US
James Rosinski - Nutley NJ, US

Assignee:

Hoffmann-La Roche Inc. - Nutley NJ

International Classification:

C12Q001/68
G01N033/53
G01N033/567

US Classification:

435006000, 435007200

Abstract:

The present invention provides polypeptides which are correlated with pre-diabetes, diabetes or susceptibility to diabetes which can be used as markers for diagnosis of pre-diabetes, diabetes or a susceptibility or predisposition to develop diabetes. The invention also provides methods for the diagnosis of pre-diabetes, diabetes and/or the susceptibility to diabetes by obtaining a biological sample and detecting and/or measuring the increase of one or more polypeptides as disclosed herein. Screening methods relating to agonists and antagonists of the specific polypeptides disclosed herein are provided. Antibodies may also be raised against these polypeptide markers for the detection and/or treatment of diabetes. Proteins, protein fragments or peptides can be used for the treatment of diabetes or pre-diabetes.

US Patent:

20050214794, Sep 29, 2005

Filed:

Oct 20, 2004

Appl. No.:

10/973045

Inventors:

Gayle Collin - Trenton ME, US
Jan Marshall - Mount Desert ME, US
Mitchell Martin - Verona NJ, US
Juergen Naggert - Bar Harbor ME, US
Patsy Nishina - Bar Harbor ME, US
W. So - Nutley NJ, US

International Classification:

C12Q001/68
C07H021/04
C07K014/705

US Classification:

435006000, 435069100, 435320100, 435325000, 530350000, 536023200

Abstract:

The present invention relates to a nucleic acid sequence linked to Alström syndrome, variants of that nucleic acid sequence, the protein produced by that nucleic acid sequence and screening methods for testing individuals to determine if they are carriers of Alström syndrome.

US Patent:

20060234910, Oct 19, 2006

Filed:

Mar 23, 2006

Appl. No.:

11/388155

Inventors:

W. Garvey - Mountain Brook AL, US
Yuchang Fu - Mountain Brook AL, US
Mitchell Martin - Nutley NJ, US

International Classification:

A61K 38/28
A61K 31/155
A61K 31/175

US Classification:

514002000, 514003000, 514592000, 514635000

Abstract:

The MINOR and TR3 genes are disclosed to be insulin responsive genes differentially expressed as a function of insulin resistance and Type 2 Diabetes in humans and a variety of well characterized animal models. The present disclosure shows that MINOR and TR3 have a functional role in insulin resistance. Therefore, MINOR and TR3 are attractive and novel therapeutic targets for combating insulin resistance and/or disease states and conditions characterized by insulin resistance. Correlation of insulin resistance and disease states and conditions characterized by insulin resistance, including Type II diabetes, with MINOR and TR3 gene expression are also disclosed. Methods of diagnosis, treatment and prevention are likewise disclosed for the treatment and/or prevention of insulin resistance and disease states or conditions characterized by insulin resistance.

US Patent:

20060292638, Dec 28, 2006

Filed:

Sep 1, 2006

Appl. No.:

11/514392

Inventors:

Robert Goodnow - Gillette NJ, US
David Mark - West Windsor NJ, US
Mitchell Martin - Verona NJ, US
James Rosinski - Nutley NJ, US

International Classification:

G01N 33/53

US Classification:

435007100

Abstract:

Sequence #115, a G protein-coupled receptor, has been identified as a target for identifying weight modulating compounds. Compounds that modulate sequence #115 may be useful for the treatment of obesity and cachexia. Cell-based and cell-free assays are described to identify compounds which bind to and/or activate or inhibit the activity of sequence #115.

US Patent:

20090298756, Dec 3, 2009

Filed:

Apr 24, 2006

Appl. No.:

11/912247

Inventors:

Meilei Jin - Shanghai, CN
Yun Peng - Shanghai, CN
Hong Zou - Shanghai, CN
Guoping Zhao - Shanghai, CN
Xuedong Zhou - Shanghai, CN
Anne O. Chua - Wayne NJ, US
Robert A. Goodnow - Gillette NJ, US
Ulrich A. Gubler - Glen Ridge NJ, US
Holly Hilton - Kearny NJ, US
David Fu-Chi Mark - West Windsor NJ, US
Mitchell Lee Martin - Verona NJ, US
James Andrew Rosinski - Nutley NJ, US

Assignee:

SHANGHAI INSTITUTES FOR BIOLOGICAL SCIENCES, CHINESE ACADEMY OF SCIENCES - Shanghai
F.HOFFMANN-LA ROCHE AG - Basal

International Classification:

A61K 38/17
C07K 14/71
C12Q 1/68

US Classification:

514 12, 530350, 435 6

Abstract:

The present invention provides mammalian GPR39 gene, its coded products, and the uses in regulating appetite and pain sensitivity. A pharmaceutical composition and a health product comprising GPR39 protein are also provided. The health product and the pharmaceutical composition for suppressing appetite or decreasing pain sensitivity comprise a safe and efficient amount of antagonists of mammalian GPR39 protein (for example, 0.01-99%) and a bromatologically or pharmaceutically acceptable carrier in a suitable amount (for example 1-99.99 wt %).

US Patent:

20110262462, Oct 27, 2011

Filed:

Apr 15, 2011

Appl. No.:

13/088236

Inventors:

Adam Platt - Ely, GB
Laurent Essioux - Attenschwiller, FR
Mitchell Martin - Verona NJ, US
Soren Germer - Maplewood NJ, US
Jianmei Wang - Welwyn Garden City, GB

Assignee:

Roche Molecular Systems, Inc. - Pleasanton CA

International Classification:

A61K 39/395
C12Q 1/68
A61P 29/00
C40B 40/06

US Classification:

4241731, 506 16, 435 611

Abstract:

The present invention provides single nucleotide polymorphisms (SNPs) associated with clinical responsiveness of rheumatoid arthritis patients to treatment with an interleukin-6 receptor antibody such as tocilizumab, and methods of using such SNPs for predicting clinical response to treatment with the antibody.